Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all

被引:43
|
作者
Grebely, Jason [1 ]
Hajarizadeh, Behzad [1 ]
Lazarus, Jeffrey V. [2 ]
Bruneau, Julie [3 ,4 ]
Treloar, Carla [5 ]
机构
[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[2] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain
[3] Ctr Hosp Univ Montreal, CHUM Res Ctr, Montreal, PQ, Canada
[4] Univ Montreal, Dept Family & Emergency Med, Fac Med, Montreal, PQ, Canada
[5] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
HCV; Drug users; Injecting; Treatment; Care; Access; PWID; SUSTAINED VIROLOGICAL RESPONSE; PRESCRIPTION OPIOID INJECTION; HCV INFECTION; RISK-FACTORS; GLOBAL PREVALENCE; UNITED-STATES; PEER SUPPORT; LATE RELAPSE; HEALTH-CARE; NEW-YORK;
D O I
10.1016/j.drugpo.2019.07.016
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infection that can achieve a cure in > 95% of people has provided an important tool to help achieve the global elimination targets. Encouragingly, therapy is highly effective among people receiving opioid agonist therapy and people who have recently injected drugs. Moving forward, major challenges include ensuring that new infections are prevented from occurring and that people who are living with HCV are tested, linked to care, treated, receive appropriate follow-up, and have equitable access to care. This editorial highlights key themes and articles in a special issue focusing on the elimination of HCV among people who inject drugs. An overarching consideration flowing from this work is how to ensure equitable access to HCV treatment and care for all. This special issue maps the field in relation to: HCV prevention; the cascade of HCV care; strategies to enhance testing, linkage to care, and treatment uptake; and HCV treatment and reinfection. In addition, papers draw attention to the 'risk environments' and socio-ecological determinants of HCV acquisition, barriers to HCV care, the importance of messaging around the side-effects of new direct-acting antiviral therapies, the positive transformative potential of treatment and cure, and the key role of community-based drug user organizations in the HCV response. While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico
    Wagner, Katherine
    Zhong, Yuna
    Teshale, Eyasu
    White, Kirsten
    Winstanley, Erin L.
    Hettema, Jennifer
    Thornton, Karla
    Bisztray, Birgitta
    Fiuty, Philip
    Page, Kimberly
    DRUG AND ALCOHOL DEPENDENCE, 2021, 220
  • [32] Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada
    Jacka, Brendan
    Applegate, Tanya
    Poon, Art F.
    Raghwani, Jayna
    Harrigan, P. Richard
    DeBeck, Kora
    Milloy, M. -J.
    Krajden, Mel
    Olmstead, Andrea
    Joy, Jeffrey B.
    Marshall, Brandon D. L.
    Hayashi, Kanna
    Pybus, Oliver G.
    Lima, Viviane Dias
    Magiorkinis, Gkikas
    Montaner, Julio
    Lamoury, Francois
    Dore, Gregory J.
    Wood, Evan
    Grebely, Jason
    JOURNAL OF HEPATOLOGY, 2016, 64 (06) : 1247 - 1255
  • [33] Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
    Day, Emma
    Broder, Tina
    Bruneau, Julie
    Cruse, Sally
    Dickie, Melisa
    Fish, Suzanne
    Grillon, Celine
    Luhmann, Niklas
    Mason, Kate
    McLean, Elizabeth
    Trooskin, Stacey
    Treloar, Carla
    Grebely, Jason
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 66 : 87 - 93
  • [34] Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas, Ilias
    Sypsa, Vana
    Anagnostou, Olga
    Martin, Natasha
    Vickerman, Peter
    Kafetzopoulos, Evangelos
    Hatzakis, Angelos
    ADDICTION, 2017, 112 (07) : 1290 - 1299
  • [35] Hepatitis C Virus Vaccines Among People Who Inject Drugs
    Cox, Andrea L.
    Thomas, David L.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 : S46 - S50
  • [36] Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All
    Bruggmann, Philip
    Litwin, Alain H.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 : S56 - S61
  • [37] Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore
    Hackman, Jada
    Falade-Nwulia, Oluwaseun
    Patel, Eshan U.
    Mehta, Shruti H.
    Kirk, Gregory D.
    Astemborski, Jacquie
    Ray, Stuart C.
    Thomas, David L.
    Laeyendecker, Oliver
    INFECTION GENETICS AND EVOLUTION, 2020, 77
  • [38] Staff-Facilitated Telemedicine Care Delivery for Treatment of Hepatitis C Infection among People Who Inject Drugs
    Kim, Rebecca G.
    Mcdonell, Claire
    Mckinney, Jeff
    Catalli, Lisa
    Price, Jennifer C.
    Morris, Meghan D.
    HEALTHCARE, 2024, 12 (07)
  • [39] The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
    Harris, Magdalena
    Albers, Eliot
    Swan, Tracy
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2015, 26 (10) : 963 - 969
  • [40] Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study
    Grebely, Jason
    Alavi, Maryam
    Micallef, Michelle
    Dunlop, Adrian J.
    Balcomb, Anne C.
    Phung, Nghi
    Weltman, Martin D.
    Day, Carolyn A.
    Treloar, Carla
    Bath, Nicky
    Haber, Paul S.
    Dore, Gregory J.
    ADDICTION, 2016, 111 (02) : 311 - 319